- Home
- REE vs GDTC Comparison
REE vs GDTC Comparison
Compare REE & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- GDTC
- Stock Information
- Founded
- REE 2011
- GDTC 2018
- Country
- REE Israel
- GDTC Singapore
- Employees
- REE N/A
- GDTC N/A
- Industry
- REE Auto Manufacturing
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- GDTC Health Care
- Exchange
- REE Nasdaq
- GDTC Nasdaq
- Market Cap
- REE 22.4M
- GDTC 24.8M
- IPO Year
- REE N/A
- GDTC 2023
- Fundamental
- Price
- REE $0.74
- GDTC $1.85
- Analyst Decision
- REE Strong Buy
- GDTC
- Analyst Count
- REE 2
- GDTC 0
- Target Price
- REE $11.75
- GDTC N/A
- AVG Volume (30 Days)
- REE 129.4K
- GDTC 141.0K
- Earning Date
- REE 12-16-2025
- GDTC 01-01-0001
- Dividend Yield
- REE N/A
- GDTC N/A
- EPS Growth
- REE N/A
- GDTC N/A
- EPS
- REE N/A
- GDTC N/A
- Revenue
- REE $183,000.00
- GDTC $573,193.00
- Revenue This Year
- REE $327.73
- GDTC $5.37
- Revenue Next Year
- REE $36,888.82
- GDTC N/A
- P/E Ratio
- REE N/A
- GDTC N/A
- Revenue Growth
- REE N/A
- GDTC 63.03
- 52 Week Low
- REE $0.53
- GDTC $1.65
- 52 Week High
- REE $11.72
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- REE 37.61
- GDTC 41.78
- Support Level
- REE $0.66
- GDTC $1.78
- Resistance Level
- REE $0.99
- GDTC $2.29
- Average True Range (ATR)
- REE 0.11
- GDTC 0.24
- MACD
- REE -0.02
- GDTC -0.02
- Stochastic Oscillator
- REE 22.23
- GDTC 13.57
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.